semaglutide and cardiovascular outcomes in obesity without diabetes journal club 2.4 mg delivered a statistically significant 20% risk reduction major adverse events – REGENHEALTHSOLUTIONS (RHS) Evaluating the Cardiovascular Benefits of

As Prime Therapeutics observed: "This real-world study finds that persistence and adherence to these products is substantially lower than what has been reported in clinical trials"

Manufactured using validated peptide synthesis methodologies

Understanding Your Individual Response With Genetic Testing The PlexusDx Precision Peptide Genetic Test ($298) analyzes FTO and MC4R variants that relate to GLP-1 and related signaling pathways

Funding This study was not funded by any agency or industry

Anderson, Erik Christiansen, Azadeh Houshmand-regaard and Easwaran Manigandan own stocks or shares in Novo Nordisk

Researchers have tested it in animals for its regenerative effects